Cargando…

A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma

BACKGROUND: Immune checkpoint inhibitors are promising tools in combating several cancers, including head and neck squamous cell carcinoma (HNSCC). However, a substantial portion of HNSCC patients do not respond to PD-L1 antibody. Here we describe a photodynamic therapeutic (PDT) approach to enhance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuang, Wang, Ding, Cheng, Jinzhang, Sun, Jicheng, Kalvakolanu, Dhan V., Zhao, Xue, Wang, Di, You, Yunhan, Zhang, Ling, Yu, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635135/ https://www.ncbi.nlm.nih.gov/pubmed/36329529 http://dx.doi.org/10.1186/s12967-022-03707-x

Ejemplares similares

GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses
por: Nallar, Shreeram C., et al.
Publicado: (2008)

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
por: Falchook, Gerald S., et al.
Publicado: (2016)

Necroptosis is Related to Anti-PD-1 Treatment Response and Influences the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
por: Wang, Qiwei, et al.
Publicado: (2022)

Anti–PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment
por: Hua, Yonghong, et al.
Publicado: (2022)

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model
por: Tan, Chunrui, et al.
Publicado: (2013)

Roles for the methyltransferase SETD8 in DNA damage repair
por: Xu, Libo, et al.
Publicado: (2022)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

Photodynamic Therapy as a Potent Radiosensitizer in Head and Neck Squamous Cell Carcinoma
por: Cho, Won Jin, et al.
Publicado: (2021)

HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
por: Wang, Jian, et al.
Publicado: (2019)

Anti-PAI-1 Monoclonal Antibody Inhibits the Metastasis and Growth of Esophageal Squamous Cell Carcinoma
por: Zheng, Yutian, et al.
Publicado: (2023)

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
por: Gray, Michael, et al.
Publicado: (2015)

Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
por: Garzon-Muvdi, Tomas, et al.
Publicado: (2018)

Transduction of human dendritic cells with adenovirus encoding anti-PD-1 reduces PD-1 expression on co-cultured T cells
por: Patricia, Santos, et al.
Publicado: (2014)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma
por: Mimikos, Christina, et al.
Publicado: (2016)

Lipid-Coated Polymeric Nanoparticles for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinomas
por: Roschenko, Valeri, et al.
Publicado: (2023)

Humanization and Characterization of an Anti-Human TNF-α Murine Monoclonal Antibody
por: Chiu, Wei-Chun, et al.
Publicado: (2011)

Anti‐murine Antibody Response to Mouse Monoclonal Antibodies in Cancer Patients
por: Sakahara, Harumi, et al.
Publicado: (1997)

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
por: Zhu, Ping, et al.
Publicado: (2023)

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model
por: Li, Pan, et al.
Publicado: (2022)

Co‐delivery of dendritic cell vaccine and anti‐PD‐1 antibody with cryomicroneedles for combinational immunotherapy
por: Chang, Hao, et al.
Publicado: (2022)

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies
por: Metzger, Philipp, et al.
Publicado: (2018)

Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
por: Zhu, Peng, et al.
Publicado: (2021)

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.
por: Ledermann, J. A., et al.
Publicado: (1988)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Anti‐PD‐1 monoclonal antibody‐resistant esophageal squamous cell carcinoma showing the abscopal effect: A case report with T‐cell receptor/B‐cell receptor repertoire analysis
por: Takehara, Yuka, et al.
Publicado: (2023)

Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma
por: Feng, Liang, et al.
Publicado: (2022)

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
por: Furkert, Chris, et al.
Publicado: (2023)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Hypoxia promotes the tolerogenic phenotype of plasmacytoid dendritic cells in head and neck squamous cell carcinoma
por: Fan, Cui, et al.
Publicado: (2021)

Inhibition of murine B and T lymphopoiesis in vivo by an anti- interleukin 7 monoclonal antibody
Publicado: (1993)

Dendritic Cells in Chronic Mycobacterial Granulomas Restrict Local Anti-Bacterial T Cell Response in a Murine Model
por: Schreiber, Heidi A., et al.
Publicado: (2010)

Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity
por: Zhivaki, Dania, et al.
Publicado: (2020)

Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy
por: Wang, Ding, et al.
Publicado: (2021)

Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f0nhobq2v9m573ug2slpjmhpnh